Clinical Trial Update: Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial of NDI-034858 in moderate to severe plaque psoriasis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• NDI-034858

Snippet

Sponsor: Takeda | Conditions: Moderate to Severe Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2023-09-28